Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
By, Admin1 min read
Share
Sosei Group Corporation an international biopharmaceutical company and world-leader in GPCR1-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
